Journal of Internal Medicine & Pharmacology (JIMP)

[E-ISSN: 3049-0049]

Journal Homepage: https://sennosbiotech.com/JIMP/1



Review Article

Vitiligo: A Systematic and Comprehensive Review of Current Research and Treatment Trend

Dr. Vishal Gurumukhi

Department of Pharmaceutical Quality Assurance, Shreeyash Institute of Pharmaceutical Education and Research, Chhatrapati Sambhaji Nagar, India

ARTICLEINFO

ABSTRACT

Vitiligo is a chronic, acquired pigmentary disorder that manifests as well-demarcated depigmented macules and patches on the skin and mucous membranes. This condition arises due to the selective destruction of melanocytes, the pigment-producing cells, resulting in loss of skin color. Although vitiligo does not pose any direct threat to physical health, its cosmetic disfigurement often has profound psychological, social, and emotional consequences. The etiopathogenesis of vitiligo is multifaceted, involving complex interactions between genetic susceptibility, autoimmunity, oxidative stress, and neurochemical imbalances. Recent advancements in research have shed light on novel therapeutic targets, offering hope for improved management strategies. This review aims to provide a detailed understanding of vitiligo by exploring its epidemiology, pathogenesis, clinical features, classification, diagnostic tools, current and emerging treatment modalities, psychosocial impacts, and future directions in therapeutic development

Keywords: Vitiligo, Melanocyte destruction, Autoimmune skin disorder, Depigmentation, Phototherapy, Topical corticosteroids

**** Corresponding author**

Dr. Vishal Gurumukhi*

Department of Pharmaceutical Quality Assurance, Shreeyash Institute of Pharmaceutical Education and Research, Chhatrapati Sambhaji Nagar, India

E-mail addresses: hodqa@syppharmacy.org

Received date: 15-Mar-2025 Revised date: 23-Mar-2025 Accepted date:15-Apr-2025

1. Introduction

Vitiligo is a widely recognized acquired dermatological disorder characterized by the gradual and often unpredictable loss of skin pigmentation, which occurs due to the destruction or functional impairment of melanocytes—the specialized cells responsible for producing melanin, the pigment that gives color to the skin, hair, and eyes. Although the disorder is not physically harmful and does not affect internal organ systems, it holds significant psychosocial importance due to the visible nature of the lesions, which can lead to distress, social stigma, and a diminished quality of life, particularly in societies where appearance heavily influences self-esteem and social interactions. The exact cause of vitiligo remains elusive, but extensive research indicates a multifactorial pathogenesis involving complex interactions among genetic susceptibility, environmental triggers, immune system dysfunction, and oxidative stress. It is considered a polygenic disorder with environmental modifiers that influence the onset and progression of depigmentation [1].

Epidemiologically, vitiligo is distributed globally, affecting individuals across all ethnicities, geographical regions, and socioeconomic groups. The disease shows no strong gender predilection, although some studies suggest a higher rate of treatment-seeking behavior in females, possibly due to greater concern about cosmetic appearance. Onset can occur at any age, but nearly 50% of cases begin before the age of 20, with some patients presenting symptoms in early childhood and others experiencing onset well into adulthood. The condition often begins insidiously, with small white macules that gradually enlarge and coalesce into larger patches [2]. These depigmented areas are especially prominent on sun-exposed regions such as the face, neck, hands, and arms, as well as around natural body openings like the mouth, eyes, genitals, and anus. Mucosal surfaces and hair follicles may also be involved, resulting in leukotrichia (white or graying hair within the depigmented areas), which further complicates the visual appearance of the disease [3].

The clinical course of vitiligo is highly variable. While some individuals may experience spontaneous repigmentation, others may show progressive depigmentation over months or years. Factors such as emotional stress, skin trauma, and certain chemical exposures

have been associated with disease initiation or exacerbation, though definitive causality remains unproven. A hallmark feature known as the Koebner phenomenon—where new lesions develop at sites of injury or trauma—illustrates the skin's heightened sensitivity in affected individuals and reflects the possible role of mechanical stress in lesion formation [4].

Despite being medically benign and non-contagious, the absence of a universally effective treatment and the unpredictable natural history of vitiligo present significant challenges in its clinical management. The condition often demands a multidisciplinary approach that combines dermatological expertise, psychological support, and patient education to manage both the physical and emotional dimensions of the disease. Given the advancements in immunology and molecular biology, there is growing hope for more effective, targeted therapies in the future. However, until a definitive cure is discovered, comprehensive and compassionate care remains the cornerstone of vitiligo management [5].

2. Epidemiology

The prevalence of vitiligo varies worldwide, affecting an estimated 0.5% to 2% of the global population. This discrepancy may be attributed to differences in reporting methods, population genetics, and environmental exposures. The condition occurs in all racial groups, but it tends to be more noticeable and distressing in individuals with darker skin due to the stark contrast between affected and unaffected skin. While both sexes are equally susceptible, women are often more likely to seek medical consultation, possibly due to cosmetic and societal concerns. Vitiligo can appear at any age, but it commonly begins during the first two decades of life. In some populations, a familial pattern is observed, suggesting a hereditary predisposition. Comorbidities are not uncommon, particularly autoimmune conditions such as autoimmune thyroiditis, type 1 diabetes, and alopecia areata, which further complicate management [6].

Table.1: Epidemiological and Clinical Characteristics of Vitiligo.

Parameter	Data
Global prevalence	0.5% to 2%
Peak onset age	10 to 30 years

Gender ratio	Equal (1:1)
Common comorbidities	Autoimmune thyroid disease, type 1 diabetes, alopecia areata

3. Etiopathogenesis

The pathogenesis of vitiligo is highly complex, involving a confluence of genetic, immunological, biochemical, and environmental factors that culminate in melanocyte destruction. The autoimmune hypothesis posits that cytotoxic CD8+ T lymphocytes target melanocytes, driven by a dysregulated immune system that mistakenly identifies these cells as foreign. Supporting this hypothesis is the presence of circulating melanocyte-specific autoantibodies and T-cell infiltrates in the perilesional skin. The oxidative stress theory suggests that melanocytes in vitiligo patients have an impaired ability to neutralize reactive oxygen species, leading to cellular apoptosis [7]. Elevated levels of hydrogen peroxide and reduced activity of antioxidant enzymes such as catalase are consistently observed. Genetic studies have identified multiple susceptibility loci associated with both immune regulation and melanocyte biology, such as NLRP1, TYR, and PTPN22. Additionally, neurochemical mediators may play a role in segmental vitiligo, where an imbalance in neuropeptides and catecholamines results in melanocyte damage. The integration of these mechanisms points to a multifactorial origin of vitiligo, where genetic predisposition interacts with environmental and endogenous triggers [8].

4. Classification of Vitiligo

Clinically, vitiligo can be categorised into several types based on the pattern and extent of depigmentation. Non-segmental vitiligo (NSV), the most prevalent form, is characterized by symmetric, bilateral white patches that often progress over time. It typically follows a chronic course with periods of stability and exacerbation. Segmental vitiligo (SV), in contrast, manifests unilaterally and often follows a dermatomal distribution [9]. This type is more common in younger individuals and tends to stabilize more rapidly. Mixed vitiligo exhibits features of both NSV and SV. Universal vitiligo is a rare and severe form in which more than 80% of the body surface area is depigmented. Focal vitiligo is limited to one or a few areas without a clear pattern or distribution. Accurate classification is essential for determining prognosis and guiding treatment decisions,

as different types of vitiligo may respond differently to therapy [10].

Table.2: Clinical Types of Vitiligo and Their Descriptions.

Type	Description
Non-segmental vitiligo (NSV)	Bilateral and symmetrical depigmented patches
Segmental vitiligo (SV)	Unilateral patches in a dermatomal distribution
Mixed vitiligo	Features of both SV and NSV
Universal vitiligo	>80% body surface area affected
Focal vitiligo	Localized patches not following dermatomes

5. Clinical Features

The appearance of white or depigmented macules and patches on the skin primarily characterizes Vitiligo. These lesions are typically milky white, well-demarcated, and can vary in size and shape. Common sites of involvement include the face, neck, hands, feet, and areas around body orifices such as the mouth, eyes, and genitals. In some cases, mucous membranes and hair follicles may also be affected, leading to depigmentation of the lips, oral mucosa, and white hair (leukotrichia). The condition is generally asymptomatic, although some patients report mild itching or burning sensations at the onset of lesion formation. The progression of vitiligo is unpredictable, with some patients experiencing rapid spread while others have long periods of stability. The Koebner phenomenon, where new lesions develop at sites of trauma, is frequently observed and can contribute to disease exacerbation. The visibility of the lesions and their unpredictable nature often contribute to significant psychological distress in affected individuals [12].

6. Diagnostic Methods

The diagnosis of vitiligo is primarily clinical, based on the characteristic appearance and distribution of lesions.

However, several ancillary investigations can support the diagnosis and help rule out other hypopigmentary disorders. Wood's lamp examination is a non-invasive tool that emits ultraviolet light, causing depigmented areas to fluoresce brightly, enhancing their visibility and aiding early detection. Skin biopsy, though rarely required, may be performed to confirm the absence of melanocytes in the basal layer of the epidermis. Immunohistochemical staining for melanocyte markers such as MART-1 or Melan-A can provide additional confirmation [13]. Laboratory investigations may include thyroid function tests, antinuclear antibodies, and blood glucose levels to screen for associated autoimmune conditions. Photographic documentation is essential for monitoring disease progression and response to treatment. In some cases, dermoscopy may reveal specific patterns such as perifollicular pigmentation or trichrome lesions, aiding in diagnosis and therapeutic planning.

7. Treatment Modalities

7.1 Topical Therapies

Topical therapies are considered the first line of treatment in patients with localized or early-stage vitiligo. Among these, topical corticosteroids are most commonly used due to their anti-inflammatory and immunosuppressive properties. These agents work by inhibiting the local immune response, which is believed to target melanocytes in vitiligo. Potent corticosteroids such as clobetasol propionate can be highly effective in inducing repigmentation, especially when initiated early in the disease course. Treatment duration and potency must be carefully regulated to minimize adverse effects such as skin atrophy, striae, telangiectasia, and tachyphylaxis. Lower potency corticosteroids are preferred for use on the face and intertriginous regions to reduce the risk of side effects.Calcineurin inhibitors like tacrolimus and pimecrolimus represent a safer alternative to corticosteroids, particularly in areas of delicate skin [14]. These agents inhibit T-cell activation and cytokine release without causing skin thinning, making them suitable for long-term use. Studies have shown that tacrolimus ointment is especially effective in facial vitiligo, with noticeable repigmentation in several weeks. Although slower in action compared to corticosteroids, their favorable safety profile makes them ideal for pediatric patients and for maintenance therapy after achieving initial control with steroids. The

combination of topical calcineurin inhibitors with phototherapy has also shown synergistic effects, offering improved outcomes in clinical practice [15].

7.2 Phototherapy

Phototherapy remains the cornerstone for treating generalized vitiligo and is especially effective in patients with widespread involvement or rapidly progressing disease. Narrowband ultraviolet B (NB-UVB) phototherapy, delivering a wavelength of 311–313 nm, is currently considered the gold standard. It promotes repigmentation by stimulating residual melanocytes in the hair follicles, enhancing their proliferation, migration, and melanin production. NB-UVB also exerts immunomodulatory effects by reducing inflammatory cytokines and altering T-cell responses [16].

Treatment typically involves 2–3 sessions per week over a period of several months, with noticeable repigmentation generally observed after 20–30 sessions. The efficacy is higher in areas such as the face and trunk, while acral sites like hands and feet are less responsive. NB-UVB is well tolerated and suitable for both adults and children. Another form of phototherapy is the 308-nm excimer laser, which provides targeted phototherapy to small, stable lesions. It is particularly useful for localized patches and is associated with fewer sessions and quicker results, making it suitable for patients seeking focused treatment with minimal systemic exposure [17].

7.3 Systemic Therapies

Systemic therapies are reserved for rapidly progressive or refractory cases of vitiligo that do not respond adequately to topical or phototherapy alone. Oral corticosteroids are commonly employed to halt disease progression. The mini-pulse regimen, which involves administering low doses of corticosteroids intermittently (e.g., on two consecutive days per week), has shown effectiveness in controlling disease activity while minimizing systemic side effects such as weight gain, hypertension, and glucose intolerance.

In cases where corticosteroids are contraindicated or inadequate, immunosuppressive agents like methotrexate, azathioprine, and cyclosporine may be used. These drugs suppress autoimmune activity but require regular monitoring for potential hematologic, hepatic, or renal toxicity. Methotrexate, for example, is used at low weekly doses and may induce repigmentation when combined with

phototherapy. Cyclosporine, though effective, is limited by nephrotoxicity and its immunosuppressive nature. The decision to initiate systemic therapy must be individualized, taking into account disease severity, patient comorbidities, and risk-benefit ratio [18].

7.4 Surgical Interventions

Surgical options are indicated for patients with stable vitiligo—defined as no new lesions or expansion of existing lesions for at least 6 to 12 months—who have failed to respond to medical treatments. The primary goal of surgical interventions is to transfer melanocytes from normally pigmented donor skin to depigmented recipient areas, thereby restoring pigmentation. Techniques include suction blister epidermal grafting, split-thickness skin grafting, and melanocyte–keratinocyte transplantation procedures.

Suction blister grafting involves creating superficial blisters on pigmented skin using negative pressure, then transplanting the epidermal layer onto depigmented areas. This method is minimally invasive and has a high success rate, especially on the face and trunk. Split-thickness grafting involves harvesting thin layers of skin from donor sites and applying them to recipient areas; this technique is more invasive but effective for larger lesions. Melanocyte–keratinocyte transplantation is a more advanced procedure where melanocytes and keratinocytes are isolated from donor skin, cultured, and then applied to dermabraded recipient sites. These surgical methods are generally safe and effective, but the outcome depends heavily on careful patient selection, surgical expertise, and proper post-operative care [19].

7.5 Adjunctive and Emerging

Therapies Recent years have witnessed significant advancements in the understanding and treatment of vitiligo. One of the most promising developments involves Janus kinase (JAK) inhibitors, such as ruxolitinib and tofacitinib. These agents target the JAK-STAT signaling pathway, which is involved in the inflammatory process that leads to melanocyte destruction. Topical ruxolitinib has shown notable efficacy in re-pigmenting facial and non-facial lesions in clinical trials, and it was approved by the FDA in 2022 for the treatment of non-segmental vitiligo.Another area of interest is the use of antioxidants to counteract oxidative stress, a key factor in vitiligo pathogenesis. Compounds such as vitamin E, vitamin C, and ginkgo biloba have demonstrated modest benefits as adjunctive

treatments, especially when combined with other therapies. Although not curative, they may enhance the effectiveness of phototherapy and improve patient outcomes.

Camouflage techniques, including cosmetic makeup and self-tanning agents, offer immediate aesthetic improvement and can significantly enhance quality of life, particularly in visible areas. Micropigmentation or tattooing may be considered in patients with stable vitiligo who desire permanent cosmetic correction. Psychological counseling and support remain critical components of comprehensive care, as vitiligo often causes emotional distress, social anxiety, and reduced self-esteem. Integrating mental health services into vitiligo management can help address these issues and improve overall well-being [20].

Table 3: Summary of Treatment Modalities

Modality	Indication	Advantages	Limitations
Topical steroids	Localized vitiligo	Easy to use	Long-term side effects
NB-UVB	Generalized vitiligo	Effective and safe	Requires frequent visits
JAK inhibitors	Active vitiligo	Targeted therapy	Still under investigation
Calcineurin inhibitors	Facial or pediatric use	Minimal side effects	Slower onset
Systemic steroids	Rapidly progressive vitiligo	Can arrest progression	Systemic side effects
Skin grafting	Stable, localized vitiligo	High repigmentation rate	Requires surgical expertise

8. Psychosocial Impact

Vitiligo extends beyond a skin condition; it is often a deeply distressing psychosocial challenge for affected individuals. The visibility of white patches, especially on exposed parts of the body such as the face, hands, and neck, can lead to significant emotional suffering. Patients commonly report feelings of embarrassment, low self-worth, and social withdrawal. In many cultures, vitiligo is misunderstood or associated with negative stereotypes, resulting in social stigma, discrimination, and even marital or employment challenges. These psychosocial consequences are particularly pronounced among children and adolescents, who may face teasing, bullying, and isolation from peers.

Depression and anxiety disorders are frequently observed among vitiligo patients, highlighting the need for psychological evaluation and intervention as part of the treatment protocol. The unpredictable and often chronic nature of the disease contributes further to psychological distress, as patients must cope with the uncertainty of disease progression and treatment outcomes. Addressing these concerns requires a compassionate, multidisciplinary approach. Psychological counseling, support groups, and cognitive behavioral therapy can be invaluable in helping patients develop coping strategies and build resilience. Raising public awareness and promoting acceptance of vitiligo through advocacy and education are also essential steps in reducing stigma and enhancing patient quality of life [9].

9. Recent Advances and Research Recent

The pathogenesis of vitiligo have paved the way for novel and more targeted therapeutic approaches. A major focus of current research is the role of cytokine signaling, particularly the JAK-STAT pathway, which has led to the development of JAK inhibitors as targeted immunomodulatory therapies. Ruxolitinib and tofacitinib have demonstrated efficacy in early clinical trials and are poised to become standard therapies pending further validation. Their ability to halt autoimmune destruction and promote repigmentation marks a significant advance in vitiligo management.

Stem cell therapy represents another innovative avenue under investigation. Preliminary studies suggest that mesenchymal stem cells may promote melanocyte regeneration and modulate immune responses, offering dual benefits for vitiligo treatment. Additionally, gene

editing technologies such as CRISPR/Cas9 hold the potential to correct genetic mutations associated with vitiligo, although these approaches are still in experimental stages and face ethical and technical challenges.Biomarker discovery is also gaining traction, aiming to identify indicators that can predict disease activity, therapeutic response, and prognosis. This would enable personalized treatment plans, optimizing outcomes while minimizing unnecessary interventions. Combination therapies—integrating JAK inhibitors, phototherapy, and antioxidants—are being evaluated to enhance efficacy and durability of repigmentation. These recent developments reflect a shift toward precision medicine, where treatment is tailored to individual patient profiles based on genetic, immunologic, and clinical factors. With continued research and innovation, the future of vitiligo treatment appears increasingly hopeful [20].

Conclusion

Vitiligo is a chronic, acquired disorder that has far-reaching effects beyond its physical manifestations. It results from the progressive destruction or dysfunction of melanocytes, leading to visible depigmented patches on the skin. Despite being medically benign, the emotional and social toll of the condition can be profound, influencing the psychological well-being and social functioning of patients across all age groups. While the pathogenesis remains multifactorial and complex—implicating autoimmunity, oxidative stress, and genetic predispositions—advancements in our understanding of these mechanisms have opened new avenues for targeted treatments.Therapeutic approaches now range from traditional topical corticosteroids and phototherapy to newer systemic therapies, surgical interventions, and emerging immunomodulators like JAK inhibitors. Each modality presents unique advantages and limitations, necessitating a personalized treatment strategy. In parallel, the importance of addressing the psychosocial aspects of vitiligo cannot be overstated. Comprehensive care must integrate dermatological management with psychological support to improve quality of life and self-esteem.

Continued research, greater awareness, and innovative clinical strategies are critical for improving outcomes and ultimately finding a cure. As our understanding deepens and treatment modalities expand, there is renewed hope for vitiligo patients—not only for restoration of skin pigmentation

but also for reclaiming confidence and emotional well-being in their lives.

Conflict of Interest

The authors declare no competing interests.

Funding

No funding received.

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article

References

1. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. *Lancet*. 2015;386(9988):74–84.
2. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. *J Am Acad Dermatol*. 2011;65(3):473–491.
3. Taieb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. *Pigment Cell Res*. 2007;20(1):27–35.
4. Rashighi M, Harris JE. Vitiligo pathogenesis and emerging treatments. *Dermatol Clin*. 2017;35(2):257–265.
5. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. *J Am Acad Dermatol*. 2017;77(1):1–13.
6. Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. *Cochrane Database Syst Rev*. 2015;(2):CD003263.
7. Speeckaert R, van Geel N. Vitiligo: an update on pathophysiology and treatment options. *Am J Clin Dermatol*. 2017;18(6):733–744.
8. Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. *J Autoimmun*. 2005;25 Suppl:63–68.
9. Parsad D, Pandhi R, Dogra S, Kanwar AJ. Clinical study of repigmentation patterns with different treatment modalities in vitiligo. *J Eur Acad Dermatol Venereol*. 2004;18(6):683–686.
10. Huggins RH, Janusz CA, Schwartz RA. Vitiligo: a sign of systemic disease. *Indian J Dermatol Venereol Leprol*. 2006;72(1):68–71.
11. Patel N, Jahan-Tigh RR, Clark LN, Tosti A. Emerging treatments in vitiligo: a review. *J Clin Aesthet Dermatol*. 2021;14(1):27–33.

12. Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for the treatment of vitiligo: a randomised, controlled, phase 3 trial. *N Engl J Med*. 2022;387(16):1445–1455.
13. Kim NH, Choi Y, Kim JH, et al. The efficacy of narrowband UVB phototherapy in vitiligo patients with different disease duration. *J Dermatolog Treat*. 2013;24(5):417–421.
14. Gupta T, Sharma VK. Current status of surgical therapies for vitiligo. *Indian J Dermatol Venereol Leprol*. 2020;86(1):18–26.
15. Njoo MD, Westerhof W. Vitiligo: pathogenesis and treatment. *Am J Clin Dermatol*. 2001;2(3):167–181.
16. Dell'Anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. *Pigment Cell Res*. 2006;19(3):406–411.
17. Silverberg JI, Silverberg NB. Association between vitiligo and depression in US adults. *Br J Dermatol*. 2014;170(1):115–121.
18. Picardo M, Taïeb A, editors. *Vitiligo*. Springer; 2010.
19. Seçkin HY, Kibar M, Doğan G, et al. Evaluation of antioxidant status in patients with vitiligo. *Clin Exp Dermatol*. 2011;36(5):437–440.
20. van Geel N, Speeckaert R. Advances in the pathogenesis and treatment of vitiligo: a narrative review. *Clin Rev Allergy Immunol*. 2021;61(3):302–316.